Ironwood Pharmaceuticals, Inc. (IRWD) — Financial statements
Income statement, balance sheet, and cash flow for Ironwood Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 296↓15.7% | 351↓20.6% | 443↑7.8% | 411↓0.8% | 414 | |
| Cost of Revenue | 0.00↓100.0% | 8↑22.8% | 6↑333.6% | 1↓98.0% | 70 | |
| Gross Profit | 296↓13.9% | 344↓21.2% | 437↑6.7% | 409↑19.2% | 343 | |
| Operating Expenses | ||||||
| R&D Expenses | 95↓14.6% | 111↓4.0% | 116↑162.3% | 44↓37.1% | 70 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 82 | 0.00 | 0.00↓100.0% | 116 | 0.00 | |
| Other Expenses | 0.00↓100.0% | 139↓89.0% | 1,266↑89375.9% | -1↓103.5% | 41 | |
| Operating Expenses | 177↓29.3% | 251↓81.9% | 1,382↑770.1% | 159↑43.0% | 111 | |
| Total Costs & Expenses | 177↓31.3% | 258↓81.4% | 1,388↑766.2% | 160↓11.7% | 181 | |
| Operating Results | ||||||
| Operating Income | 119↑27.5% | 93↑109.8% | -945↓477.7% | 250↑7.8% | 232 | |
| Depreciation & Amortization | 2↓6.5% | 2↑27.7% | 2↑11.1% | 1↓6.9% | 2 | |
| EBITDA | 105↑7.1% | 98↓50.5% | 197↓24.5% | 261↑11.9% | 234 | |
| EBIT | 103↑7.4% | 96↓51.1% | 196↓24.7% | 260↑12.0% | 232 | |
| Interest & Other Income | ||||||
| Net Interest Income | -29↓0.4% | -29↓974.7% | -3↓239.7% | 2↑106.3% | -30 | |
| Interest Income | 4↓8.8% | 4↓76.4% | 19↑99.7% | 10↑1208.7% | 0.73 | |
| Interest Expense | 33↓0.9% | 33↑52.7% | 22↑184.7% | 8↓75.6% | 31 | |
| Non-Operating Income | 16↑716.6% | -3↑99.8% | -1,141↓11686.3% | -10↓22106.8% | 0.04 | |
| Other Income / Expenses | -49↓74.5% | -28↓958.2% | -3↓226.6% | 2↑106.6% | -32 | |
| Income Before Tax | 70↑7.4% | 65↑106.9% | -948↓475.6% | 252↑25.8% | 201 | |
| Income Tax Expense | 46↓28.5% | 64↓23.0% | 83↑7.9% | 77↑123.6% | -328 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 24↑2629.2% | 0.88↑100.1% | -1,032↓689.2% | 175↓66.9% | 528 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 24↑2629.2% | 0.88↑100.1% | -1,002↓672.5% | 175↓66.9% | 528 | |
| Bottom-Line Net Income | 24↑2629.2% | 0.88↑100.1% | -1,002↓658.3% | 180↓66.0% | 528 | |
| EPS (Basic) | 0.15↑2627.3% | 0.01↑100.1% | -6.45↓670.8% | 1.13↓65.3% | 3.26 | |
| EPS (Diluted) | 0.15↑2627.3% | 0.01↑100.1% | -6.45↓771.9% | 0.96↓70.1% | 3.21 | |
| Weighted Average Shares | 162↑2.0% | 159↑2.3% | 155↑0.7% | 154↓4.9% | 162 | |
| Weighted Average Diluted Shares | 178↑11.0% | 160↑3.0% | 155↓16.6% | 186↑13.3% | 164 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.